M&T Bank Corp Lowers Holdings in AbbVie Inc. $ABBV

Key Points

• M&T Bank Corp cut its stake in AbbVie by 59.5% in Q4, selling 569,008 shares and leaving 386,679 shares valued at about $88.35 million.
• Institutional ownership remains high at 70.23% and Wall Street is broadly constructive, with a MarketBeat consensus rating of "Moderate Buy" and a consensus price target of $253.43 (several firms set targets near $260).
• AbbVie beat Q4 estimates (EPS $2.71 vs. $2.65), provided FY2026 guidance of $14.37–$14.57 EPS, and announced a quarterly dividend of $1.73 (annualized $6.92, ~3.4% yield).

M&T Bank Corp decreased its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 59.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 386,679 shares of the company's stock after selling 569,008 shares during the quarter. M&T Bank Corp's holdings in AbbVie were worth $88,352,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of AbbVie by 0.3% in the third quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company's stock valued at $41,155,601,000 after purchasing an additional 448,554 shares during the period. Legal & General Group Plc boosted its stake in shares of AbbVie by 4.3% in the third quarter. Legal & General Group Plc now owns 12,004,084 shares of the company's stock valued at $2,779,426,000 after purchasing an additional 493,420 shares during the period. Wellington Management Group LLP boosted its stake in shares of AbbVie by 457.4% in the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock valued at $2,439,714,000 after purchasing an additional 8,646,424 shares during the period. Amundi boosted its stake in shares of AbbVie by 15.6% in the third quarter. Amundi now owns 10,508,317 shares of the company's stock valued at $2,418,909,000 after purchasing an additional 1,414,621 shares during the period. Finally, Ameriprise Financial Inc. boosted its stake in shares of AbbVie by 4.4% in the third quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company's stock valued at $2,241,363,000 after purchasing an additional 408,426 shares during the period. Hedge funds and other institutional investors own 70.23% of the company's stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Canaccord initiated coverage with a Buy and $262 price target, calling AbbVie a “core holding” and highlighting a “solid and visible” growth profile built on three franchise pillars — the note reinforces a sizable upside vs. current levels and may boost investor demand. Canaccord Calls AbbVie a Core Holding With a $262 Target: Is This Biopharma’s Most Durable Compounder?
• Positive Sentiment: RBC (and other Street bulls) continue to view ABBV as a top large-cap buy; RBC’s maintained Buy and ~$260 target keeps analyst sentiment constructive and supports multiple buy-side narratives. AbbVie (ABBV) Is One Of The Major Stock To Buy According To Wall Street
• Positive Sentiment: AbbVie hit a third milestone under its neurology collaboration (Nxera), triggering a ~$10M payment — a concrete, near-term validation of deal progress and a reminder that partnership milestones could add non-dilutive value and future upside. Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
• Positive Sentiment: Retail/independent bullish pieces continue to buy the dip, framing AbbVie’s dividend, pipeline and buybacks as durable supports — this persistent investor interest can amplify rebounds on positive catalysts. Why I Can’t Stop Buying AbbVie Stock
• Neutral Sentiment: AbbVie is sponsoring a new BioLabs facility in Toronto — a strategic R&D/innovation move that supports ecosystem development but has limited near-term revenue impact. AbbVie Sponsors New BioLabs Facility in Toronto
• Neutral Sentiment: AbbVie launched a cross‑agency psoriasis marketing campaign (“PSO Done”) — helpful for brand awareness and adoption but unlikely to move near-term top-line materially on its own. AbbVie launches ‘PSO Done’ psoriasis campaign with a cross-agency effort
• Negative Sentiment: Zacks warns AbbVie’s oncology franchise faces pressure — Imbruvica declines and pricing headwinds may weigh on Q1 top-line growth, a near-term risk to revenue expectations and investor sentiment. Will AbbVie’s Oncology Franchise Weigh on Q1 Top-line Growth?
• Negative Sentiment: Recent coverage noted ABBV shares pulled back and underperformed the broader market in the latest session — a sign of profit taking and sensitivity to near-term growth concerns that could amplify downside absent fresh positive catalysts. Here's Why AbbVie (ABBV) Fell More Than Broader Market

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ABBV. Guggenheim lifted their price target on shares of AbbVie from $242.00 to $249.00 and gave the stock a "buy" rating in a research note on Friday, April 10th. Canaccord Genuity Group began coverage on shares of AbbVie in a research note on Monday. They issued a "buy" rating and a $262.00 price target for the company. Sanford C. Bernstein reiterated a "market perform" rating on shares of AbbVie in a research note on Thursday, February 5th. Evercore decreased their price target on shares of AbbVie from $232.00 to $228.00 and set an "outperform" rating for the company in a research note on Wednesday, February 4th. Finally, Morgan Stanley lifted their price target on shares of AbbVie from $269.00 to $270.00 and gave the stock an "overweight" rating in a research note on Thursday, February 5th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $253.43.

Insider Activity at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of the business's stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the business's stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares of the company's stock, valued at $8,771,510. This represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is currently owned by insiders.

AbbVie Trading Up 0.6%

Shares of NYSE:ABBV opened at $204.95 on Wednesday. The company has a market capitalization of $362.38 billion, a PE ratio of 86.84, a P/E/G ratio of 0.73 and a beta of 0.38. AbbVie Inc. has a twelve month low of $170.91 and a twelve month high of $244.81. The firm has a 50 day simple moving average of $218.27 and a 200-day simple moving average of $222.93.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company's revenue was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities research analysts predict that AbbVie Inc. will post 14.26 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.4%. The ex-dividend date is Wednesday, April 15th. AbbVie's payout ratio is currently 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.